Literature DB >> 18376398

Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone.

Yasushi Sato1, Kazuyuki Murase, Junji Kato, Masayoshi Kobune, Tsutomu Sato, Yutaka Kawano, Rishu Takimoto, Kouichi Takada, Koji Miyanishi, Takuya Matsunaga, Tetsuji Takayama, Yoshiro Niitsu.   

Abstract

There are currently no approved antifibrotic therapies for liver cirrhosis. We used vitamin A-coupled liposomes to deliver small interfering RNA (siRNA) against gp46, the rat homolog of human heat shock protein 47, to hepatic stellate cells. Our approach exploits the key roles of these cells in both fibrogenesis as well as uptake and storage of vitamin A. Five treatments with the siRNA-bearing vitamin A-coupled liposomes almost completely resolved liver fibrosis and prolonged survival in rats with otherwise lethal dimethylnitrosamine-induced liver cirrhosis in a dose- and duration-dependent manner. Rescue was not related to off-target effects or associated with recruitment of innate immunity. Receptor-specific siRNA delivery was similarly effective in suppressing collagen secretion and treating fibrosis induced by CCl(4) or bile duct ligation. The efficacy of the approach using both acute and chronic models of liver fibrosis suggests its therapeutic potential for reversing human liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18376398     DOI: 10.1038/nbt1396

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  168 in total

1.  Endoplasmic reticulum oxidase 1α is critical for collagen secretion from and membrane type 1-matrix metalloproteinase levels in hepatic stellate cells.

Authors:  Mizuki Fujii; Akihiro Yoneda; Norio Takei; Kaori Sakai-Sawada; Marina Kosaka; Kenjiro Minomi; Atsuro Yokoyama; Yasuaki Tamura
Journal:  J Biol Chem       Date:  2017-08-03       Impact factor: 5.157

Review 2.  Targeting collagen expression in alcoholic liver disease.

Authors:  Kyle J Thompson; Iain H McKillop; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

3.  Thymosin-β4 (Tβ4) blunts PDGF-dependent phosphorylation and binding of AKT to actin in hepatic stellate cells.

Authors:  Karina Reyes-Gordillo; Ruchi Shah; Anastas Popratiloff; Sidney Fu; Anna Hindle; Frederick Brody; Marcos Rojkind
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 4.  Gene therapy for liver regeneration: experimental studies and prospects for clinical trials.

Authors:  Hussein-M Atta
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

Review 5.  Cellular endocytosis and gene delivery.

Authors:  Jennifer E Ziello; Yan Huang; Ion S Jovin
Journal:  Mol Med       Date:  2010-02-03       Impact factor: 6.354

Review 6.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 7.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

8.  Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis.

Authors:  Toshiaki Teratani; Kengo Tomita; Takahiro Suzuki; Hirotaka Furuhashi; Rie Irie; Makoto Nishikawa; Junji Yamamoto; Toshifumi Hibi; Soichiro Miura; Tohru Minamino; Yuichi Oike; Ryota Hokari; Takanori Kanai
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

Review 9.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 10.  Targeted delivery systems for oligonucleotide therapeutics.

Authors:  Bo Yu; Xiaobin Zhao; L James Lee; Robert J Lee
Journal:  AAPS J       Date:  2009-03-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.